201 related articles for article (PubMed ID: 32097841)
1. Design, synthesis, and pharmacological evaluation of 4- or 6-phenyl-pyrimidine derivatives as novel and selective Janus kinase 3 inhibitors.
Shu L; Chen C; Huan X; Huang H; Wang M; Zhang J; Yan Y; Liu J; Zhang T; Zhang D
Eur J Med Chem; 2020 Apr; 191():112148. PubMed ID: 32097841
[TBL] [Abstract][Full Text] [Related]
2. Structure-based design and synthesis of pyrimidine-4,6-diamine derivatives as Janus kinase 3 inhibitors.
Yu RN; Chen CJ; Shu L; Yin Y; Wang ZJ; Zhang TT; Zhang DY
Bioorg Med Chem; 2019 Apr; 27(8):1646-1657. PubMed ID: 30853331
[TBL] [Abstract][Full Text] [Related]
3. Novel 1H-pyrazolo[3,4-d]pyrimidin-6-amino derivatives as potent selective Janus kinase 3 (JAK3) inhibitors. Evaluation of their improved effect for the treatment of rheumatoid arthritis.
Yin Y; Chen CJ; Yu RN; Shu L; Wang ZJ; Zhang TT; Zhang DY
Bioorg Chem; 2020 May; 98():103720. PubMed ID: 32171982
[TBL] [Abstract][Full Text] [Related]
4. Design and Synthesis of a Highly Selective JAK3 Inhibitor for the Treatment of Rheumatoid Arthritis.
He L; Pei H; Lan T; Tang M; Zhang C; Chen L
Arch Pharm (Weinheim); 2017 Nov; 350(11):. PubMed ID: 28944566
[TBL] [Abstract][Full Text] [Related]
5. Structure-based design and synthesis of 1H-pyrazolo[3,4-d]pyrimidin-4-amino derivatives as Janus kinase 3 inhibitors.
Yin Y; Chen CJ; Yu RN; Wang ZJ; Zhang TT; Zhang DY
Bioorg Med Chem; 2018 Sep; 26(17):4774-4786. PubMed ID: 30139575
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and SAR study of highly potent, selective, irreversible covalent JAK3 inhibitors.
He L; Shao M; Wang T; Lan T; Zhang C; Chen L
Mol Divers; 2018 May; 22(2):343-358. PubMed ID: 29411195
[TBL] [Abstract][Full Text] [Related]
7. Development of Selective Covalent Janus Kinase 3 Inhibitors.
Tan L; Akahane K; McNally R; Reyskens KM; Ficarro SB; Liu S; Herter-Sprie GS; Koyama S; Pattison MJ; Labella K; Johannessen L; Akbay EA; Wong KK; Frank DA; Marto JA; Look TA; Arthur JS; Eck MJ; Gray NS
J Med Chem; 2015 Aug; 58(16):6589-606. PubMed ID: 26258521
[TBL] [Abstract][Full Text] [Related]
8. VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease.
Mahajan S; Hogan JK; Shlyakhter D; Oh L; Salituro FG; Farmer L; Hoock TC
J Pharmacol Exp Ther; 2015 May; 353(2):405-14. PubMed ID: 25762693
[TBL] [Abstract][Full Text] [Related]
9. Highly selective Janus kinase 3 inhibitors based on a pyrrolo[2,3-d]pyrimidine scaffold: evaluation of WO2013085802.
Norman P
Expert Opin Ther Pat; 2014 Jan; 24(1):121-5. PubMed ID: 24147573
[TBL] [Abstract][Full Text] [Related]
10. The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3.
Lee SM; Yoon KB; Lee HJ; Kim J; Chung YK; Cho WJ; Mukai C; Choi S; Kang KW; Han SY; Ko H; Kim YC
Bioorg Med Chem; 2016 Nov; 24(21):5036-5046. PubMed ID: 27555284
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of JAK3 Biology in Autoimmune Disease Using a Highly Selective, Irreversible JAK3 Inhibitor.
Elwood F; Witter DJ; Piesvaux J; Kraybill B; Bays N; Alpert C; Goldenblatt P; Qu Y; Ivanovska I; Lee HH; Chiu CS; Tang H; Scott ME; Deshmukh SV; Zielstorff M; Byford A; Chakravarthy K; Dorosh L; Rivkin A; Klappenbach J; Pan BS; Kariv I; Dinsmore C; Slipetz D; Dandliker PJ
J Pharmacol Exp Ther; 2017 May; 361(2):229-244. PubMed ID: 28193636
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors.
Ren J; Shi W; Zhao D; Wang Q; Chang X; He X; Wang X; Gao Y; Lu P; Zhang X; Xu H; Zhang Y
Bioorg Med Chem; 2020 Jan; 28(2):115236. PubMed ID: 31843459
[TBL] [Abstract][Full Text] [Related]
13. Discovery of diaminopyrimidine-carboxamide derivatives as JAK3 inhibitors.
Bahekar R; Panchal N; Soman S; Desai J; Patel D; Argade A; Gite A; Gite S; Patel B; Kumar J; S S; Patel H; Sundar R; Chatterjee A; Mahapatra J; Patel H; Ghoshdastidar K; Bandyopadhyay D; Desai RC
Bioorg Chem; 2020 Jun; 99():103851. PubMed ID: 32334196
[TBL] [Abstract][Full Text] [Related]
14. Novel Pyrimidines as Multitarget Protein Tyrosine Kinase Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis (IPF).
Sun B; Liu X; Zheng X; Wang C; Meng Q; Sun H; Shu X; Liu K; Sun X; Li Y; Ma X
ChemMedChem; 2020 Jan; 15(2):182-187. PubMed ID: 31755225
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting.
Forster M; Gehringer M; Laufer SA
Bioorg Med Chem Lett; 2017 Sep; 27(18):4229-4237. PubMed ID: 28844493
[TBL] [Abstract][Full Text] [Related]
16. Discovery of an Orally Available Janus Kinase 3 Selective Covalent Inhibitor.
Shi L; Zhong Z; Li X; Zhou Y; Pan Z
J Med Chem; 2019 Jan; 62(2):1054-1066. PubMed ID: 30615446
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological activity of thieno[3,2-d]pyrimidines as potent JAK3 inhibitors for the treatment of idiopathic pulmonary fibrosis.
Zhu Y; Zheng X; Wang C; Sun X; Sun H; Ma T; Li Y; Liu K; Chen L; Ma X
Bioorg Med Chem; 2020 Jan; 28(2):115254. PubMed ID: 31866272
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of cyano-substituted 2,4-diarylaminopyrimidines as potent JAK3 inhibitors for the treatment of B-cell lymphoma.
Wu B; Yang S; Deng T; Wang C; Jin Y; Yu J; Xu Y; Chen L; Li Y; Ma X
Bioorg Chem; 2021 Nov; 116():105330. PubMed ID: 34547646
[TBL] [Abstract][Full Text] [Related]
19. Tricyclic covalent inhibitors selectively target Jak3 through an active site thiol.
Goedken ER; Argiriadi MA; Banach DL; Fiamengo BA; Foley SE; Frank KE; George JS; Harris CM; Hobson AD; Ihle DC; Marcotte D; Merta PJ; Michalak ME; Murdock SE; Tomlinson MJ; Voss JW
J Biol Chem; 2015 Feb; 290(8):4573-4589. PubMed ID: 25552479
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3.
Nakajima Y; Inoue T; Nakai K; Mukoyoshi K; Hamaguchi H; Hatanaka K; Sasaki H; Tanaka A; Takahashi F; Kunikawa S; Usuda H; Moritomo A; Higashi Y; Inami M; Shirakami S
Bioorg Med Chem; 2015 Aug; 23(15):4871-4883. PubMed ID: 26071372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]